Analytical agreement and platform-specific decision thresholds for plasma p-tau217 measured on Lumipulse G600II and Cobas e801 in a paired CSF-plasma cohortMaría Martínez-Bujidoson May 5, 2026 at 10:00 am
Clin Chem Lab Med. 2026 May 5. doi: 10.1515/cclm-2026-0395. Online ahead of print. ABSTRACT OBJECTIVES: Plasma phosphorylated tau at threonine 217 (p-tau217) has emerged as a highly accurate blood-based biomarker of Alzheimer’s disease (AD) pathology. As disease-modifying anti-amyloid therapies enter clinical practice, scalable biomarkers with robust and clinically interpretable decision thresholds are required. However, evidence … Read more